NO20045249L - Epotilonderivat for behandling av hepatom og andre kreftsykdommer - Google Patents

Epotilonderivat for behandling av hepatom og andre kreftsykdommer

Info

Publication number
NO20045249L
NO20045249L NO20045249A NO20045249A NO20045249L NO 20045249 L NO20045249 L NO 20045249L NO 20045249 A NO20045249 A NO 20045249A NO 20045249 A NO20045249 A NO 20045249A NO 20045249 L NO20045249 L NO 20045249L
Authority
NO
Norway
Prior art keywords
treatment
progressing
radiotherapy
cancer
hepatoma
Prior art date
Application number
NO20045249A
Other languages
English (en)
Norwegian (no)
Inventor
John David Rothermel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20045249L publication Critical patent/NO20045249L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silicon Polymers (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20045249A 2002-05-01 2004-11-30 Epotilonderivat for behandling av hepatom og andre kreftsykdommer NO20045249L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37706302P 2002-05-01 2002-05-01
PCT/EP2003/004581 WO2003092683A1 (en) 2002-05-01 2003-04-30 Epothilone derivative for the treatment of hepatoma and other cancer diseases

Publications (1)

Publication Number Publication Date
NO20045249L true NO20045249L (no) 2005-01-26

Family

ID=29401440

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045249A NO20045249L (no) 2002-05-01 2004-11-30 Epotilonderivat for behandling av hepatom og andre kreftsykdommer

Country Status (23)

Country Link
US (2) US20050282873A1 (pl)
EP (1) EP1503756B1 (pl)
JP (1) JP2005528414A (pl)
KR (1) KR20040106422A (pl)
CN (1) CN1649585A (pl)
AT (1) ATE439130T1 (pl)
AU (1) AU2003227702B2 (pl)
BR (1) BR0309711A (pl)
CA (1) CA2483826C (pl)
CY (1) CY1109607T1 (pl)
DE (1) DE60328772D1 (pl)
DK (1) DK1503756T3 (pl)
ES (1) ES2330324T3 (pl)
IL (1) IL164783A (pl)
MX (1) MXPA04010853A (pl)
NO (1) NO20045249L (pl)
NZ (1) NZ536178A (pl)
PL (1) PL211114B1 (pl)
PT (1) PT1503756E (pl)
RU (1) RU2358730C2 (pl)
SI (1) SI1503756T1 (pl)
WO (1) WO2003092683A1 (pl)
ZA (1) ZA200408492B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0309711A (pt) * 2002-05-01 2005-02-09 Novartis Ag Método para o tratamento de doenças do câncer
EP1663214A1 (en) * 2003-09-02 2006-06-07 Novartis AG Cancer treatment with epothilones
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
CA2597647A1 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
WO2007130501A2 (en) 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
CN101747326B (zh) * 2010-01-12 2012-07-25 山东大学 18元大环内酯类埃博霉素化合物及其应用
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
US6262094B1 (en) * 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
GB9918429D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
BR0309711A (pt) * 2002-05-01 2005-02-09 Novartis Ag Método para o tratamento de doenças do câncer

Also Published As

Publication number Publication date
CY1109607T1 (el) 2014-08-13
US20080161369A1 (en) 2008-07-03
DK1503756T3 (da) 2009-11-16
HK1073601A1 (en) 2005-10-14
WO2003092683A1 (en) 2003-11-13
EP1503756A1 (en) 2005-02-09
RU2358730C2 (ru) 2009-06-20
CA2483826C (en) 2012-04-17
AU2003227702A1 (en) 2003-11-17
PL371727A1 (pl) 2005-06-27
PT1503756E (pt) 2009-10-28
EP1503756B1 (en) 2009-08-12
IL164783A (en) 2011-08-31
IL164783A0 (en) 2005-12-18
PL211114B1 (pl) 2012-04-30
BR0309711A (pt) 2005-02-09
AU2003227702B2 (en) 2007-07-26
NZ536178A (en) 2007-10-26
CA2483826A1 (en) 2003-11-13
DE60328772D1 (de) 2009-09-24
ZA200408492B (en) 2006-09-27
KR20040106422A (ko) 2004-12-17
CN1649585A (zh) 2005-08-03
ES2330324T3 (es) 2009-12-09
MXPA04010853A (es) 2005-02-14
SI1503756T1 (sl) 2010-01-29
JP2005528414A (ja) 2005-09-22
RU2004135307A (ru) 2005-09-10
ATE439130T1 (de) 2009-08-15
US20050282873A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
CY1109607T1 (el) Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων
PH12019502586A1 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
EA201201154A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
RU2014108042A (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
RU2012140185A (ru) Ингибирование ангиогенеза
EA201290062A1 (ru) Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
RU2014128513A (ru) Раковый маркер и терапевтическая мишень
RU2008150250A (ru) Способ лечения рака
ATE461713T1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
DE602005015304D1 (de) Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer
WO2006031756A3 (en) Betulinol derivatives as anti-cancer agents
MX2024005434A (es) Inhibidores de ddr1 y ddr2 para el tratamiento de cancer y enfermedades fibroticas.
EA200970949A1 (ru) Способы лечения неоплазии при помощи комбинации химиотерапевтических агентов и облучения
TW200732305A (en) Cancer chemotherapy
DE602004014965D1 (de) Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
NO20055650D0 (no) Ruteinum (II)-komplekser for behandling av tumorer
JPWO2021183873A5 (pl)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application